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Epidemiology of Hepatocellular Carcinoma 
in Florida – Part I: A Statewide Report 
 
Angel E. Alsina, MD, Aryan Beharry, Narrad Beharry, PhD, MSPH,  
Nyingi Kemmer, MD, Edson Franco, MD, Haydy Rojas, RN, Guy W. Neff, MD 
 
ABSTRACT 
The increasing incidence of hepatocellular carcinoma (HCC) has become a burgeoning public health problem. The effect has 
been most notable at liver transplant centers. Traditional reports of liver cancer include many non-HCC variants. This study 
aims at determining the incidence of HCC in the state of Florida, utilizing data from Florida Cancer Data Systems. This 
study pertains exclusively to HCC. Of 2,296,794 cancer cases, 4,447 HCC and variants were identified (68.7%). Incidence 
rates were as follows. The incidence of HCC in the state of Florida was 6.1 cases /100,000 population/year; Male: 
9.6/100,000 population/year vs.  Female: 2.7; Whites: 6.5/100,000 population/year vs. Blacks: 5.3; Hispanics: 4.6/100,000 
population/year vs. Non-Hispanics: 6.5. Limitations of the study included lack of etiology of liver disease, treatments and 
survival.  The classification of tumors and under-reporting in the database are also concerns. The study elaborates on guide-
lines for screening and diagnosis of HCC. The incidence of HCC in Florida in this study was three times higher than previous 
reports from 2 decades ago. This is the most updated study reporting the incidence of HCC in Florida, although data was 5 
years old. The incidence of this cancer is expected to continue to increase over the next decade. The study is a preamble to so-
cioeconomic and county studies currently being performed at this liver transplant center.  
Florida Public Health Review, 2012; 9, 18-23. 
 
Background 
Hepatocellular carcinoma (HCC), a primary ma-
lignancy of the liver and one of the most common 
malignancies worldwide accounts for more than 1 
million deaths annually. The increasing incidence of 
HCC has started to become a burgeoning public 
health problem.  Recent publications during the past 
40 years have noted a significant rise in the inci-
dence of HCC within the United States (Altekruse, 
McGlynn, & Reichman, 2009). 
The geographic distribution of HCC has been 
linked to a multitude of risk factors: Hepatitis B vi-
rus and Hepatitis C virus being the two most impli-
cated factors. It has been shown that the distribution 
of HCC is closely related to the incidence of hepatitis 
B/C virus infection. Therefore, not surprisingly, 
because the high rates of horizontal transmission of 
hepatitis B, the highest incidences of HCC are found 
in Southeast Asia and Africa (greater than 10 to 20 
per 100,000), whilst the lowest incidence is found in 
Australia, North America and Europe (1-3 per 
100,000). 
HCC has been demonstrated to be the third 
leading cause of cancer mortality worldwide (Alte-
kruse et al., 2009). It has also been shown that ap-
proximately 90% of primary liver carcinomas within 
the United States are HCC, while the remaining 10 
percent are cholangiocarcinomas. It has been estab-
lished throughout literature that a large percent of 
HCC is significantly associated with hepatitis viral 
infection, while other factors include alcohol use, 
smoking, genetic metabolic disease, cirrhosis, envi-
ronmental exposure, chronic infections and family 
history of liver cancer. 
Over the past 20 years, the age adjusted inci-
dence of HCC has nearly tripled in the United 
States, ignited by the unforeseen incidence of chron-
ic Hepatitis C and Hepatitis B. At present there are 4 
million US citizens afflicted with chronic Hepatitis C 
and 1.2 million afflicted with chronic hepatitis B. 
Like the rest of the U.S., the incidence of liver cancer 
has increased significantly within the state of Flori-
da. Whether the increased incidence is related to 
immigration, increased screening, increased rate of 
hepatitis B or hepatitis C infection, cirrhosis, obesi-
ty/diabetes mellitus or a combination has yet to be 
determined. HCC is the fastest growing cause of 
cancer-related deaths in the U.S. (National Cancer 
Institute [NCI], 2006) and has the highest mortality 
in the obese population (Calle, Rodriguez, Thun & 
Walker-Thurmond 2003). 
Previous reports of liver cancer in Florida come 
from two recent sources. In 2001, from the Depart-
ment of Epidemiology and Public Health, the overall 
incidence between 1985 and 1995 was 2.01/100,000 
population; 3.29/100,000 in Hispanics; 1.82/100,000 
in white males; 3.86/100,000 in Black males; 
1.23/100,000 and 1.18/100,000 in Hispanic and 
Black females, respectively; and 0.6/100,000 in 
White females (Shea, Fleming, Wilkinson, Wohler-
Torres, & McKinnon, 2001). The second study was 
from the Bureau of Epidemiology, Florida Depart-
ment of Health (DOH) (Florida Department of 
Health: Bureau of Epidemiology [DOHBOE], 
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2005). In this 2005 study, 1,127 new cases of liver 
cancer were diagnosed that year. The age adjusted 
incidence was 5.1 per 100,000 population. This rate 
was below the national incident rate of 6.8% and 2.5 
times higher than the incident rate in 1981. Mortali-
ty was 3.9 per 100,000 population (below national 
rate of 5.3), and 45% higher than in 1981, with 890 
Floridians dying of liver cancer in 2005. 
This study aims at determining the incidence of 
HCC in the state of Florida, utilizing data from 
FCDS which contains all liver cancer types. Differ-
ent from the 2005 DOH report on Epidemiology of 
Liver Cancer, this study pertains exclusively to he-
patocellular carcinoma and its variants. Therefore, 
our study has the most updated incidence data and 
characteristics of HCC in Florida. It is unique in this 
respect. The study is a preamble to socioeconomic 
studies of HCC and transplant center studies on 
HCC performed by our liver transplant center. 
 
Methods 
Available data for liver cancer in Florida comes 
primarily from The Florida Cancer Data System 
(FCDS), Florida’s statewide population based cancer 
registry (DOHBOE, 2005). The system has collected 
cancer incidence data since 1981. The last report on 
liver cancer came in 2005, collected by FCDS under 
contract by the DOH. The data does not include 
cancers diagnosed before a person became a Florida 
resident. The FCDS has achieved the highest stan-
dard and received “Gold Certification” for quality, 
completeness, and timeliness for the data collected 
for each year from 2000 to 2005. 
The FCDS implemented case-finding strategies 
to ensure a complete database. Mortality follow-back 
was implemented to identify unreported cancer cases 
from death data. Death certificates were checked 
annually. A process implemented by the FCDS uses 
hospital discharge data from the Florida Agency of 
Health Care Administration (AHCA) to identify 
missed cases and compared to the FCDS database. 
Cancer cases that are identified in the AHCA data 
and that are missing in the FCDS database are “fol-
lowed back” to the hospital to obtain complete re-
ports. This procedure has also been employed to 
ascertain new cancer cases from ambulatory surgical 
centers. 
The STAT CD from FCDS, containing data for 
the years 1983 to 2010, with a total of 2,296,794 
cancer cases was decoded using the Data Acquisition 
Manual, 2009. The site code 2627 actually included 
both liver (HCC) and intrahepatic bile duct cancer, 
or cholangiocarcinomas (CCA) (ICCD-9 155, 155.2, 
and 155.1; ICD-03 is C22 and C22.1), and other liver 
tumors. We included only data for the 2004-2008 
period, the most recent time period, as reported in 
FCDS and our period of interest. All age ranges 
were included. Only HCC cases were selected for 
analysis. Incident cases for each county were re-
ported per 100,000 population per year. Population 
data were obtained from the U.S. Census Report 
(U.S. Census Bureau [USCB]) and from the FCDS 
2010 Hispanic Report (Fleming 2001, 2010; Her-
nandez, 2010; Lee, 2010; MacKinnon, 2001, 2010). 
The Stat CD data was transferred to an Excel pro-
gram and files compressed using statistical program 
J zip version 1.3. Fisher’s exact 2-tailed tests were 
utilized, with p values less than 0.05 deemed signifi-
cant. Permission from FCDS to conduct the research 
and approval from the University of South Florida 
Institutional Review Board was obtained. 
The following variables were analyzed: age, 
ethnicity, race, tumor grade, marital status, diagnos-
tic methods, morphology (histologic type), sex, stage 
(local, regional, distant), insurance payer, and county 
of origin at time of tumor diagnosis. Since 59% of 
cases had unknown grade, this variable was not fur-
ther analyzed. Non-Hispanics likely included Blacks 
and Asians, making ethnicity composition question-
able. This is explained in the 2010 FCDS Hispanic 
report (Hernandez, et al. 2010), as follows: [“His-
panics” include both Blacks and Whites in part be-
cause this follows the patterns of Hispanic race-
ethnic self-identification (i.e., Black Hispanics often 
identify as “Hispanics” rather than “Black”), and be-
cause the numbers of identified Black Hispanics in 
the FCDS database are quite small. These analyses 
do not include non-Hispanic Blacks who are a mix-
ture of African Americans and Blacks from other 
countries (particularly the Caribbean)]. Stepwise 
case-finding of HCC cases is described below. 
 
Results 
Originally, the study began with 2,296,794 can-
cer cases. Of these cases, 6,474 were classified as 
liver tumors. Among the liver tumors, there were 
2,025 (31.3%) non-HCC and 4,447 (68.7 %) HCC. 
The non-HCC tumors included adenomas, benign 
tumors, cholangiocarcinomas, vascular tumors, and 
many other variants. Cholangiocarcinomas ac-
counted for 9.6% of all tumors. HCC and variants 
are depicted in Table 1. Only the tumors in Table 1 
were included in the incidence study and comprised 
all HCC cases. Incidence rates were as follows. The 
incidence of HCC in the state of Florida was 6.1 cas-
es /100,000 population/year; Male: 9.6/100,000 
population/year vs.  Female: 2.7/100,000 popula-
tion/year; Whites: 6.5/100,000 population/year vs.  
Blacks: 5.3/100,000 population/year; Hispanics: 
4.6/100,000 population/year vs. Non-Hispanics: 
6.5/100,000 population/year. 
Table 2 displays percentages of all study va-
riables. Males, Whites and Non-Hispanics were the 
predominated variables. Uninsured HCC patients 
comprised 7.9 % of all HCC cases. Tumor grade was 
not recorded in 59% of HCC cases. Only 43% of the 
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Table 1. HCC Cases 2004-2008 
__________________________________________ 
No. % HCC 
 
Mixed HCC/CCA 70 1.5 
Clear cell  29 0.6 
Fibrolamellar  16 0.3 
HCC NOS  4320 97 
Pleomorphic  1        < 0.001 
Spindle cell  13 0.2 
__________________________________________ 
 
Total                         4,447       
NOS = Not otherwise specified 
 
cases presented with local disease. HCC cases peaked 
at age 50-59 (1,435 cases, or 358/yr) (Table3). No 
difference in staging was observed among different 
age groups. However, there were more uninsured 
cases in the 30-59 age compared to 60-89 (16% vs. 
2.6%, p=.0001). 
A detailed county incidence study has been con-
ducted and will be reported separately. The frequen-
cy of counties at incidence range of 0-4/100,000 
population was 20%; at 5-6/100,000 was 44%; at 6-
7/100,000 was 24% and at 7-9/100,000 was 22%. 
Union County was an outlier, with 33 HCC cases for 
an incidence of 56.8/100,000 population. It also con-
tained the largest proportion of Blacks as percentage 
of total HCC cases (51%).  
 
Discussion 
Our study updates the incidence of HCC in 
Florida for the period between 2004 and 2008. The 
incidence was 6.1 cases/100,000 population. Al-
though data used for this study is almost 5 years old, 
the incidence of HCC in Florida has continued to 
increase. This is based on previous state reports 
which estimated the incidence at 5.1/100,000 popu-
lation, a study that also included bile duct cancers 
(DOHBOE, 2005). As we expected, the incidence 
was similar to previous national reports on HCC 
(Altekruse et al., 2009; El-Serag et al., 2003). Com-
pared to a 1985-1995 incident HCC report, the inci-
dence tripled during the time period we examined 
(DOHBOE, 2005). Whites and Non-Hispanics com-
prised the majority of HCC cases. The  
incidence was lower in Blacks vs. Non-Blacks and 
lower in Hispanics vs. Non-Hispanics. This finding 









Table 2.  Study Variables 
___________________________________________ 
  Percent of HCC Cases    χ2 
trend 
 
Race              p < .0001 
Black      14.1             
White      85.9 
 
Ethnicity                                       p < .0001  
Hispanic      16.1            
Non-Hispanic     83.9 
 
Payer              p < .0001 
Medicaid     10.2 
Medicare     46.2 
Not Insured       7.9 
Private      30.4 
Tricare, Military, VA,  
Indian/Public Health  
Service        2.3 
Unknown       3.0 
 
Grade              p < .0001 
Well diff.     18.0 
Mod      14.4 
Poor        7.8 
Undiff        0.7 
Unknown     59.0 
 
Diagnostic Method           p < .0001 
Pos. Cytology       4.6 
Pos Histology     82.5 
Pos Micros conf       0.2 
Radiography     12.0 
Unknown       0.7 
 
Stage            p < .0001   
Local      43.0 
Regional     21.1 
Distant      14.0 
Unknown     21.3 
 
Sex            p < .0001 
Female      22.6 
Male      77.4 
__________________________________________  
 
previous data (Altekruse et al., 2009; El-Serag et al., 
2003). The FCDS database has limitations in the 
racial and ethnicity composition and we recognize 
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Table 3.  Age Distribution HCC 
__________________________________________ 
 
Decade  HCC Percent 
 
<10      0.04 
10-19      0.2 
20-29      0.5 
30-39      1.3 
40-49      8.3 
50-59    32.3 
60-69    22.0 
70-79    22.7 
80-89    12.5 
__________________________________________ 
 
high incidence of HCC, are not categorized. Inclu-
sion of liver cancers other than HCC in previous 
Florida reports may account for these differences as 
well. Characteristics of the Hispanic population in 
Florida and corresponding HCC incidence are the 
subjects of our current research. As expected, males 
predominated 3.5 to 1. Many tumors have androgen 
receptors (Nagasue et al., 2005). The preponderance 
of risk factors for HCC in males is well known. 
HCC were the tumors of interest, based on ris-
ing incidence. These tumors have accounted for as 
many as 20-30% of liver transplant indications at 
some centers, including ours. These are also cancers 
that arise from risk factors that are well known and 
we can control. In contrast, cholangiocarcinomas, 
which in this database comprised 9.6% of all tumors 
similar to previous reports of 8% (Goodman, 2007), 
have poorly defined risk factors and occur frequently 
in absence of cirrhosis. There is some concern in the 
data about the histologic classification of the tumors 
according to well established nomenclature, such as 
the WHO Histological Classification (Enjoji, 2008). 
Epithelial tumors comprise a large segment of liver 
tumors. There are benign variants, which include 
hepatocellular adenomas, focal nodular hyperplasia, 
intrahepatic bile duct adenomas and cystadenomas, 
and biliary papillomatosis. Several malignant va-
riants are also included within the epithelial tumors, 
including HCC, intrahepatic Cholangiocarcinoma, 
bile duct Cystadenocarcinoma, mixed 
HCC/Cholangiocarcinoma, Hepatoblastomas, and 
other undifferentiated tumors. There were 202 epi-
thelial tumors in the database (3.1% of all total tu-
mors, or 10% of non-HCC tumors), that were un-
classified as above, some of which were malignant 
per degree of grade reported. Some of these may 
have been HCC, possibly underscoring the true inci-
dence of HCC. 
In this report, 14% of patients with HCC were 
reported as having distant metastases and in 21% of 
the cases the staging was unknown. This is certainly 
concerning. Our liver transplant center, which spe-
cializes in HCC, has concentrated on education re-
lated to screening for liver cancer in patients that 
are at risk, based on the presence of chronic liver 
disease, cirrhosis, a positive family history and infec-
tious hepatitis, particularly chronic hepatitis B and 
C, among other risk factors. This information has to 
be spread through the oncology and gastroenterolo-
gy medical communities, but most importantly, 
through the primary care and internal medicine spe-
cialties. Guidelines for the screening, diagnosis and 
treatment of hepatocellular carcinoma came from 
published reports, most recently updated in July 
2010, and endorsed by the American Association for 
the Study of Liver Diseases (AASLD) (Bruix & 
Sherman, 2011). It consists of liver ultrasonography 
every 6 months. Patients at risk for HCC need to be 
entered into surveillance programs.  There is Level 
1 evidence for this and specific cut-offs of HCC inci-
dence at which screening becomes cost effective 
(Keefe, Lin, Keefe, Sanders & Owens, 2004). There is 
concern that ultrasonography will miss tumors, par-
ticularly in the obese, advanced cirrhotic livers and 
those with ascites. Computerized tomography or 
magnetic resonance imaging is routinely utilized in 
specialized clinics to screen at risk patients for HCC. 
Our study likely underestimates the true inci-
dence of HCC. It is our belief that many HCC cases 
go underreported in cancer databases and cancer 
registries. HCC is one of very few tumors that are 
frequently diagnosed without tissue confirmation, 
possibly making reporting the carcinomas difficult. 
HCC can be diagnosed radiologically without need 
for tissue confirmation, as long as findings on con-
trast enhanced CT scan or MRI are typical for HCC 
(Former et al., 2008). Diagnosis guidelines by imag-
ing are elaborated in the HCC Guidelines (Bruix & 
Sherman, 2011). We want to strongly emphasize 
that radiologic guidelines for HCC are to be applied 
only to patients with cirrhosis and risk factors for 
liver cancer, and not in any other circumstance. It 
should also be understood that biopsy confirmation 
of HCC presents several challenges. Not only it can 
be risky in patients with cirrhosis and portal hyper-
tension, but it can be also difficult to interpret, which 
can result in delay of diagnosis and treatment, and 
may also result in stage migration. At liver cancer 
programs and transplant centers such as ours, HCC 
is frequently diagnosed, treated with locoregional 
therapy, resection, liver transplantation and system-
ic therapy, without tissue confirmation. Another 
limitation of the study was the lack of important 
variables, including the etiologies of liver disease, 
treatments and survival. The creation of multidiscip-
linary liver cancer programs in the state of Florida, 
particularly at most of the 6 liver transplant centers, 
should be improving the overall survival of HCC. 
This study is a preamble to upcoming prospec-
tive studies on HCC. The diagnosis of HCC should 
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no longer be a death sentence. It should be recog-
nized by all those treating patients at risk for HCC, 
that the disease can be prevented (vaccination of 
Hepatitis B, treatment of hepatitis B and C), that 
careful screening can detect early disease, and that 
treatments are available for early, intermediate and 
advanced stages of the disease. Cure can be achieved 
with locoregional therapy and resection, long term 
disease free survival can be achieved with liver 
transplantation, and improved survival can now be 
achieved with transarterial chemoembolization and 
systemic therapy (Llovet et al., 2008). 
Healthy People 2020, the nation’s new 10-year 
goals for health promotion and disease prevention, 
have cancer objectives that support monitoring 
trends in cancer incidence, mortality, and survival. 
The recommendations for screening come from the 
U.S. Preventive Services Task Force (United States 
Preventative Task Force [USPSTF]). The Agency 
for Healthcare Research and Quality’s Prevention 
and Care Management Portfolio administers the 
USPSTF (United States Department and Health and 
Human Services: The Agency for Health Care Re-
search and Quality [HHSTAFHCRAQ]). Surpri-
singly, the U.S. Preventive Services Task Force does 




The incidence of hepatocellular carcinoma in 
Florida in this study was three times higher than 
previous reports from 2 decades ago (DOHBOE, 
2005). This is the most updated study reporting the 
incidence of HCC in Florida. The study utilized data 
that, on average, was 5 years old. It is not an ethnic 
and racial composition report. We expect the inci-
dence of this cancer to continue to increase over the 
next decade.  HCC remains the fastest growing can-
cer in the U.S. In our next study, we would like to 
report socioeconomic variables and perform group 
and county studies of HCC. 
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